Alcon is set to present new research on dry eye disease at the American Academy of Optometry's annual meeting, Academy 2026, in Anaheim, California. The event, running from September 30 to October 3, will showcase studies on various aspects of living with dry eye, including how treatments impact patients' lives, satisfaction with therapies, and daily functioning.
The research is part of Alcon's scientific program and will cover new findings related to Tryptyr (acoltremon ophthalmic solution) 0.003% and other treatments. Featured studies will provide insights into patient-reported outcomes, quality of life, and how treatments affect meibomian gland function, which is key to keeping the eyes moist.
For those interested in new treatments, research on Tryptyr will specifically look at how this solution might improve daily life and work abilities for people who switched from other medications, like lifitegrast. The studies are designed to understand overall satisfaction and the real-world impact of these eye treatments.
While this research could reveal interesting possibilities for managing dry eye, remember that these findings are being discussed at a conference and may still be in an exploratory phase. It's essential to talk to an eye doctor about what these developments might mean for you and whether these treatments are suitable for your condition.
Source: Eyewire+